Clinical Report: Laser-Titratable Shunt Shows Promise in Feasibility Study
Overview
The Calibreye Titratable Glaucoma Therapy system demonstrates significant intraocular pressure (IOP) reduction and medication-free outcomes in patients with moderate to severe glaucoma. Initial findings from a feasibility study indicate that the device allows for in-office adjustments to optimize patient outcomes.
Background
Managing intraocular pressure is crucial in glaucoma treatment, particularly for patients who have not responded to traditional therapies. The Calibreye system offers a novel approach by allowing real-time adjustments to aqueous flow resistance, potentially improving patient safety and treatment efficacy. This innovation could address the limitations of existing surgical options for glaucoma management.
Data Highlights
| Parameter | Value |
|---|---|
| Reduction in IOP | 44.9% |
| Average Postoperative IOP | 12.1 mmHg |
| Percentage of Patients Medication-Free | 88% |
| Mean Reduction in Medications | More than 3 medications per patient |
Key Findings
- The Calibreye system achieved a 44.9% reduction in IOP compared to baseline.
- Average postoperative IOP was recorded at 12.1 mmHg.
- 88% of patients were medication-free after the procedure.
- One case of hypotony maculopathy led to device explantation, prompting a change in implantation technique.
- The system allows for multiple in-office adjustments using a laser to control aqueous flow.
Clinical Implications
The Calibreye system represents a significant advancement in glaucoma management, offering adjustable IOP control that can be tailored to individual patient needs. Clinicians may consider this device for patients requiring precise IOP management, especially those with a history of failed surgeries.
Conclusion
The initial results from the feasibility study of the Calibreye Titratable Glaucoma Therapy system are promising, indicating its potential as a safe and effective option for managing intraocular pressure in glaucoma patients.
References
- Glaucoma Physician, 2026 -- Laser-Titratable Shunt Achieves IOP Reduction at 12 Months
- Glaucoma Physician, 2023 -- First In-human Study of Titratable Aqueous Shunt Therapy Has Begun
- Retinal Physician, 2009 -- New Approaches to Retinal Laser Therapy
- Glaucoma Physician, 2025 -- Ultrathin Shunt Shows Promising Results in Trial
- AAO Guidelines, 2024 -- Guidelines for Glaucoma
- European Glaucoma Society, 6th Edition -- Terminology and guidelines for glaucoma
- https://bdoc.info/dl/informationen/Guidelines-AAO.pdf
- European Glaucoma Society – Terminology and guidelines for glaucoma, 6th Edition | British Journal of Ophthalmology
- Laser-Titratable Shunt Achieves IOP Reduction at 12 Months | Glaucoma Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.